Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2010

01-01-2010 | Epidemiology

Breast cancer-related preferences among women with and without BRCA mutations

Authors: Victor R. Grann, Priya Patel, Anubha Bharthuar, Judith S. Jacobson, Ellen Warner, Kristin Anderson, Eiran Warner, Wei-Yann Tsai, Kimberly A. Hill, Alfred I. Neugut, Dawn Hershman

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Abstract

Preference ratings are used to quantify quality of life in analyses used for health care policymaking. Subjects indicated how many years of their life expectancy they would trade to avoid BRCA mutations, breast/ovarian cancer, and five preventive measures including prophylactic surgery, annual mammograms, and annual magnetic resonance imaging (MRI). Among 243 respondents, both the 83 women with mutations and the 160 controls rated mammography highest (most favorably), MRI next highest, having a child with a mutation lowest, and ovarian cancer next lowest. Controls rated prophylactic surgery higher than cancer (P < 0.01), but women with mutations did not. In logistic regression, controls were twice as willing as women with mutations to trade time except for screening modalities; younger, lower-income, and non-white women were more willing to trade time than older, higher-income, and white women. Our findings support the use of average-risk individuals’ time trade-off preference ratings for health care policy development.
Appendix
Available only for authorised users
Literature
3.
go back to reference Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20(10):2520–2529. doi:10.1200/JCO.2002.10.101 CrossRefPubMed Grann VR, Jacobson JS, Thomason D, Hershman D, Heitjan DF, Neugut AI (2002) Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis. J Clin Oncol 20(10):2520–2529. doi:10.​1200/​JCO.​2002.​10.​101 CrossRefPubMed
6.
go back to reference Anderson K, Jacobson JS, Heitjan DF et al (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6):397–406PubMed Anderson K, Jacobson JS, Heitjan DF et al (2006) Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144(6):397–406PubMed
7.
16.
go back to reference Gold M, Siegel J, Russell L, Weinstein M (eds) (1996) Cost-effectiveness in health and medicine New York. Oxford University Press, New York Gold M, Siegel J, Russell L, Weinstein M (eds) (1996) Cost-effectiveness in health and medicine New York. Oxford University Press, New York
17.
go back to reference Slevin ML, Stubbs L, Plant HJ et al (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300(6737):1458–1460CrossRefPubMed Slevin ML, Stubbs L, Plant HJ et al (1990) Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 300(6737):1458–1460CrossRefPubMed
18.
go back to reference Stiggelbout AM, de Vogel-Voogt E (2008) Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 11(1):76–87PubMed Stiggelbout AM, de Vogel-Voogt E (2008) Health state utilities: a framework for studying the gap between the imagined and the real. Value Health 11(1):76–87PubMed
20.
go back to reference Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5(4):559–575CrossRefPubMed Torrance GW, Feeny D (1989) Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5(4):559–575CrossRefPubMed
21.
go back to reference Grann VR, Jacobson JS, Sundararajan V et al (1999) The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5(5):283–292PubMed Grann VR, Jacobson JS, Sundararajan V et al (1999) The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5(5):283–292PubMed
23.
25.
27.
go back to reference Kirschner N, Pauker SG, Stubbs JW et al (2008) Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 148(12):956–961 Kirschner N, Pauker SG, Stubbs JW et al (2008) Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 148(12):956–961
Metadata
Title
Breast cancer-related preferences among women with and without BRCA mutations
Authors
Victor R. Grann
Priya Patel
Anubha Bharthuar
Judith S. Jacobson
Ellen Warner
Kristin Anderson
Eiran Warner
Wei-Yann Tsai
Kimberly A. Hill
Alfred I. Neugut
Dawn Hershman
Publication date
01-01-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0373-6

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine